Index RUT
P/E -
EPS (ttm) -0.39
Insider Own 50.71%
Shs Outstand 248.92M
Perf Week -6.31%
Market Cap 331.16M
Forward P/E -
EPS next Y -0.27
Insider Trans 0.00%
Shs Float 122.70M
Perf Month -4.29%
Income -95.90M
PEG -
EPS next Q -0.09
Inst Own 30.78%
Short Float 13.01%
Perf Quarter -3.59%
Sales 6.22M
P/S 53.24
EPS this Y 13.85%
Inst Trans -6.87%
Short Ratio 16.56
Perf Half Y 24.34%
Book/sh 0.48
P/B 2.79
EPS next Y 20.83%
ROA -49.78%
Short Interest 15.96M
Perf Year 12.75%
Cash/sh 0.25
P/C 5.27
EPS next 5Y 2.40%
ROE -78.37%
52W Range 0.84 - 1.88
Perf YTD -0.72%
Dividend Est. -
P/FCF -
EPS past 5Y 36.94%
ROI -77.10%
52W High -29.23%
Beta 1.77
Dividend TTM -
Quick Ratio 2.99
Sales past 5Y -20.14%
Gross Margin -58.32%
52W Low 59.25%
ATR (14) 0.07
Dividend Ex-Date -
Current Ratio 2.99
EPS Y/Y TTM -20.13%
Oper. Margin -1428.50%
RSI (14) 41.62
Volatility 4.25% 4.90%
Employees 202
Debt/Eq 0.06
Sales Y/Y TTM -88.35%
Profit Margin -1540.63%
Recom 1.80
Target Price 9.00
Option/Short Yes / Yes
LT Debt/Eq 0.05
EPS Q/Q -24.69%
Payout -
Rel Volume 0.52
Prev Close 1.32
Sales Surprise -42.47%
EPS Surprise -64.56%
Sales Q/Q -30.35%
Earnings Mar 19 AMC
Avg Volume 963.63K
Price 1.33
SMA20 -3.98%
SMA50 -8.69%
SMA200 -1.88%
Trades
Volume 74,773
Change 0.79%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-22-24 Downgrade
JP Morgan
Neutral → Underweight
May-23-23 Initiated
JP Morgan
Neutral
Nov-18-22 Initiated
Cantor Fitzgerald
Overweight
$7
Feb-25-21 Initiated
Stifel
Buy
$13
Feb-22-21 Initiated
Wells Fargo
Overweight
$14
Feb-18-21 Initiated
B. Riley Securities
Buy
$10
May-08-20 Initiated
H.C. Wainwright
Buy
$5
Apr-24-24 10:20AM
09:00AM
Mar-28-24 04:05PM
Mar-27-24 08:20AM
Mar-20-24 10:07AM
08:53PM
Loading…
Mar-19-24 08:53PM
05:31PM
04:05PM
Mar-12-24 04:05PM
Mar-05-24 04:05PM
Feb-06-24 04:05PM
Jan-16-24 08:05AM
Jan-08-24 08:30AM
Jan-02-24 12:40PM
Dec-18-23 04:05PM
04:05PM
Loading…
Nov-29-23 04:05PM
Nov-09-23 04:55PM
Nov-07-23 04:05PM
Sep-19-23 04:05PM
Aug-09-23 08:00AM
07:05AM
Aug-03-23 04:05PM
Jun-20-23 07:30AM
Jun-05-23 04:05PM
Jun-03-23 12:00PM
May-31-23 08:05AM
May-10-23 08:00AM
May-03-23 08:30AM
Apr-26-23 04:05PM
Apr-17-23 09:01AM
04:30PM
Loading…
Apr-03-23 04:30PM
Mar-29-23 08:05AM
Mar-28-23 08:05AM
Mar-06-23 04:05PM
Feb-07-23 08:00AM
Jan-30-23 02:34PM
(American City Business Journals)
Jan-27-23 04:05PM
Jan-24-23 10:40PM
04:05PM
04:01PM
Jan-11-23 06:45PM
Jan-04-23 04:05PM
Dec-27-22 08:00AM
Dec-19-22 04:05PM
Dec-12-22 07:01PM
Nov-16-22 05:07AM
Nov-09-22 04:05PM
Nov-02-22 04:30PM
Sep-21-22 04:30PM
Sep-01-22 08:05AM
Aug-22-22 08:05AM
Aug-08-22 04:05PM
Aug-05-22 08:36AM
Aug-01-22 04:05PM
Jul-06-22 08:09AM
(American City Business Journals) -9.88%
Jul-05-22 08:05AM
Jun-27-22 04:05PM
May-17-22 04:05PM
May-14-22 08:15AM
May-11-22 06:29AM
May-09-22 04:05PM
May-02-22 03:00PM
Apr-04-22 08:05AM
Apr-03-22 03:40PM
Mar-01-22 08:00AM
Feb-02-22 10:10AM
(Simply Wall St.) -10.38%
Feb-01-22 09:38PM
Jan-24-22 02:48PM
(American City Business Journals)
Jan-12-22 04:30PM
Jan-11-22 10:00AM
Jan-05-22 04:05PM
Dec-13-21 05:05PM
Dec-01-21 07:56AM
Nov-24-21 08:38AM
Nov-10-21 04:05PM
Nov-04-21 09:15AM
Nov-01-21 03:01PM
Oct-27-21 04:38PM
Oct-26-21 08:05AM
Oct-12-21 08:05AM
Oct-05-21 05:00AM
(American City Business Journals)
Oct-04-21 08:34AM
Oct-01-21 08:05AM
Sep-21-21 10:55AM
Sep-01-21 08:05AM
Aug-09-21 04:01PM
Aug-02-21 04:05PM
03:01PM
Jun-23-21 05:12AM
Jun-10-21 05:05PM
04:05PM
May-10-21 04:30PM
Apr-28-21 12:33PM
Mar-30-21 04:05PM
Mar-25-21 05:46AM
Mar-23-21 08:05AM
Mar-18-21 08:30AM
Mar-01-21 04:05PM
02:30PM
Feb-22-21 04:05PM
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
KIRK RANDAL J Director Mar 09 '24 Option Exercise 0.00 213,675 0 32,051,461 Mar 12 05:36 PM KIRK RANDAL J Director Dec 28 '23 Buy 1.41 96,686 136,327 1,096,686 Dec 29 07:30 PM KINDLER JEFFREY B Director Dec 28 '23 Sale 1.41 96,686 136,327 238,275 Dec 29 07:19 PM MITCHELL DEAN J Director Sep 22 '23 Buy 1.41 25,000 35,250 356,836 Sep 25 04:02 PM Sabzevari Helen President and CEO Aug 25 '23 Sale 1.53 76,969 117,763 1,560,004 Aug 25 07:04 PM Lehr Donald P. Chief Legal Officer Aug 24 '23 Sale 1.64 10,947 17,953 428,916 Aug 25 07:03 PM Thomasian Harry Jr. Chief Financial Officer Aug 24 '23 Sale 1.64 9,045 14,834 161,051 Aug 25 06:59 PM Perez Jeffrey Thomas SVP, IP Affairs Aug 24 '23 Sale 1.64 8,891 14,581 458,903 Aug 25 07:00 PM Shah Rutul R Chief Operating Officer Aug 24 '23 Sale 1.64 5,388 8,836 133,474 Aug 25 07:01 PM Sabzevari Helen President and CEO Aug 18 '23 Sale 1.66 55,855 92,719 1,495,386 Aug 18 09:06 PM Lehr Donald P. Chief Legal Officer Aug 17 '23 Sale 1.55 10,762 16,681 418,153 Aug 18 09:13 PM Thomasian Harry Jr. Chief Financial Officer Aug 17 '23 Sale 1.55 8,893 13,784 152,162 Aug 18 09:15 PM Perez Jeffrey Thomas SVP, IP Affairs Aug 17 '23 Sale 1.55 8,741 13,549 448,916 Aug 18 09:18 PM Shah Rutul R Chief Operating Officer Aug 17 '23 Sale 1.55 5,298 8,212 123,382 Aug 18 09:09 PM KIRK RANDAL J Director Aug 16 '23 Buy 1.51 119,411 180,311 31,837,786 Aug 17 08:19 AM KIRK RANDAL J Director Aug 15 '23 Buy 1.52 380,589 577,301 31,718,375 Aug 17 08:19 AM Hassan Fred Director Aug 14 '23 Buy 1.75 570,345 998,104 878,942 Aug 16 04:31 PM Frank Steven Director Aug 14 '23 Buy 1.72 400,000 688,000 882,358 Aug 15 04:18 PM Sabzevari Helen President and CEO Aug 11 '23 Sale 1.44 41,436 59,668 1,409,654 Aug 11 07:24 PM Lehr Donald P. Chief Legal Officer Aug 10 '23 Sale 1.21 11,026 13,341 407,205 Aug 11 07:28 PM Perez Jeffrey Thomas SVP, IP Affairs Aug 10 '23 Sale 1.21 8,956 10,837 438,779 Aug 11 07:26 PM Thomasian Harry Jr. Chief Financial Officer Aug 10 '23 Sale 1.21 6,852 8,291 143,121 Aug 11 07:27 PM Shah Rutul R Chief Operating Officer Aug 10 '23 Sale 1.21 5,429 6,569 113,200 Aug 11 07:29 PM Sabzevari Helen President and CEO Aug 04 '23 Sale 1.10 52,870 58,157 1,309,503 Aug 04 07:05 PM Lehr Donald P. Chief Legal Officer Aug 03 '23 Sale 1.20 10,821 12,985 396,521 Aug 04 07:09 PM Perez Jeffrey Thomas SVP, IP Affairs Aug 03 '23 Sale 1.20 8,789 10,547 428,857 Aug 04 07:10 PM Thomasian Harry Jr. Chief Financial Officer Aug 03 '23 Sale 1.20 6,724 8,069 132,039 Aug 04 07:08 PM Shah Rutul R Chief Operating Officer Aug 03 '23 Sale 1.20 5,328 6,394 103,149 Aug 04 07:06 PM
Index -
P/E -
EPS (ttm) -23.65
Insider Own 4.72%
Shs Outstand 17.09M
Perf Week 11.46%
Market Cap 974.13M
Forward P/E -
EPS next Y -9.63
Insider Trans 0.00%
Shs Float 16.28M
Perf Month 2.57%
Income -123.28M
PEG -
EPS next Q -2.08
Inst Own 44.56%
Short Float 4.69%
Perf Quarter 30.64%
Sales 2.45M
P/S 397.60
EPS this Y 52.66%
Inst Trans -6.16%
Short Ratio 3.73
Perf Half Y 274.38%
Book/sh 7.92
P/B 7.19
EPS next Y -8.83%
ROA -121.41%
Short Interest 0.76M
Perf Year 239.29%
Cash/sh 4.76
P/C 11.98
EPS next 5Y -14.60%
ROE -169.13%
52W Range 12.45 - 67.21
Perf YTD 155.83%
Dividend Est. -
P/FCF -
EPS past 5Y -10.28%
ROI -173.54%
52W High -15.19%
Beta 2.88
Dividend TTM -
Quick Ratio 5.39
Sales past 5Y 0.00%
Gross Margin 57.05%
52W Low 357.83%
ATR (14) 4.10
Dividend Ex-Date -
Current Ratio 5.39
EPS Y/Y TTM 66.15%
Oper. Margin -5164.41%
RSI (14) 58.28
Volatility 7.58% 7.99%
Employees 82
Debt/Eq 0.04
Sales Y/Y TTM -
Profit Margin -5037.88%
Recom 1.43
Target Price 135.00
Option/Short Yes / Yes
LT Debt/Eq 0.02
EPS Q/Q 77.14%
Payout -
Rel Volume 0.66
Prev Close 54.87
Sales Surprise -
EPS Surprise 2.68%
Sales Q/Q -
Earnings Mar 05 BMO
Avg Volume 204.72K
Price 57.00
SMA20 9.91%
SMA50 9.29%
SMA200 88.50%
Trades
Volume 20,354
Change 3.88%
Date
Action
Analyst
Rating Change
Price Target Change
Today Initiated
Robert W. Baird
Outperform
$117
Sep-19-23 Initiated
Truist
Buy
$10
Jun-06-22 Downgrade
Wedbush
Outperform → Neutral
$4
Dec-16-21 Initiated
H.C. Wainwright
Buy
$48
Aug-26-21 Initiated
BofA Securities
Buy
$28
Apr-26-21 Initiated
William Blair
Outperform
Nov-11-20 Initiated
Wedbush
Outperform
$40
Nov-10-20 Initiated
Piper Sandler
Overweight
$65
Nov-10-20 Initiated
Evercore ISI
Outperform
$55
Nov-10-20 Initiated
Cowen
Outperform
Today 07:10AM
Apr-12-24 08:00AM
Apr-11-24 12:00PM
Apr-05-24 09:00AM
Apr-02-24 05:00PM
06:23AM
Loading…
Mar-29-24 06:23AM
(The Wall Street Journal)
Mar-28-24 12:20AM
Mar-27-24 04:01PM
10:53AM
Mar-26-24 04:14PM
(Investor's Business Daily) +23.13%
09:21AM
(Investor's Business Daily)
06:30AM
Mar-25-24 04:01PM
Mar-08-24 12:00PM
Mar-07-24 01:31PM
09:55AM
Loading…
Mar-06-24 09:55AM
Mar-05-24 08:10AM
07:00AM
Mar-01-24 08:00AM
Feb-02-24 04:00PM
Jan-11-24 07:30AM
Jan-10-24 04:19PM
Jan-09-24 04:57PM
Jan-08-24 08:00AM
Jan-05-24 09:55AM
08:00AM
Nov-30-23 09:55AM
Nov-28-23 07:00AM
Nov-21-23 04:00PM
Nov-16-23 08:00AM
09:35AM
Loading…
Nov-14-23 09:35AM
Nov-07-23 08:00AM
07:00AM
Nov-02-23 08:00AM
Oct-02-23 01:17PM
Sep-27-23 04:15PM
Sep-07-23 08:00AM
Aug-31-23 08:00AM
Aug-28-23 07:00AM
Aug-17-23 10:04AM
Aug-11-23 07:00AM
Aug-09-23 07:00AM
Aug-08-23 07:00AM
Aug-07-23 07:00AM
Aug-03-23 04:12PM
Jul-14-23 10:20AM
(Simply Wall St.) -13.53%
Jun-22-23 07:00AM
Jun-17-23 09:41AM
Jun-15-23 11:58PM
04:01PM
Jun-09-23 07:00AM
Jun-02-23 09:00AM
May-11-23 01:12PM
07:30AM
06:55AM
May-07-23 09:22AM
Apr-19-23 08:00AM
Apr-17-23 08:00AM
Apr-06-23 09:00AM
Mar-03-23 04:05PM
11:05AM
07:30AM
Feb-07-23 08:00AM
Dec-13-22 04:01PM
Nov-28-22 04:05PM
08:00AM
Nov-09-22 04:01PM
05:42AM
Nov-07-22 09:00AM
Sep-26-22 06:28AM
Sep-21-22 09:00AM
Sep-20-22 08:30AM
Sep-07-22 04:05PM
10:46AM
07:30AM
Aug-08-22 04:01PM
Aug-03-22 09:00AM
Jul-11-22 02:20PM
Jun-26-22 09:47AM
Jun-07-22 11:30AM
Jun-06-22 08:39AM
07:45AM
May-23-22 09:00AM
May-13-22 12:54PM
May-11-22 09:00AM
May-10-22 08:22AM
May-09-22 04:01PM
04:01PM
May-04-22 09:00AM
May-02-22 04:15PM
Apr-27-22 08:25AM
Apr-18-22 03:08PM
Apr-13-22 08:00AM
Apr-01-22 09:00AM
Mar-21-22 09:00AM
Mar-01-22 09:00AM
Feb-28-22 06:00AM
Feb-22-22 09:00AM
Jan-18-22 09:00AM
Jan-17-22 09:07AM
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. It is a targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
DeSimone Jill Director Oct 05 '23 Buy 1.75 14,500 25,375 14,500 Oct 10 07:41 AM Souza Marcio Chief Executive Officer Jun 27 '23 Buy 1.06 10,000 10,587 45,002 Jun 27 07:52 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite